Henry Schein Q2 Results: Sales rise 6.7%, EPS up 15.5%
Henry Schein delivered strong Q2 2026 results with $3.5 billion in sales, up 6.7% YoY, and non-GAAP EPS of $1.27, a 15.5% increase. Driven by margin expansion and market share gains in dental merchandise, the company raised full-year guidance for sales growth to 4.5%-5.5% and EPS growth to 6%-8%. Strategic focus on AI-enabled technology and value creation initiatives supports long-term profitability.
*this image is generated using AI for illustrative purposes only.
Henry Schein reported second-quarter 2026 global sales of $3.5 billion, a 6.7% increase compared to the same period in 2025, driven by strong internal local currency sales growth of 4.6% and favorable foreign exchange effects. The healthcare distributor raised its full-year 2026 guidance, projecting total sales growth of 4.5% to 5.5% and non-GAAP earnings per share (EPS) growth of 6% to 8%, reflecting sustained momentum in its core dental and medical businesses alongside successful execution of value creation initiatives. This performance underscores the company’s ability to capture market share despite stable patient volumes, with strategic investments in AI-enabled technology platforms and private-label brands contributing significantly to margin expansion.
The company’s GAAP operating margin for the quarter was 4.94%, an increase of 27 basis points from the prior year, while non-GAAP operating margin reached 7.21%, up 25 basis points. GAAP net income stood at $94 million, or $0.82 per diluted share, compared to $86 million, or $0.70 per diluted share, in the prior-year period. Non-GAAP net income increased to $145 million, or $1.27 per diluted share, from $135 million, or $1.10 per diluted share, previously. Adjusted EBITDA grew 12.7% to $288 million from $256 million in the second quarter of 2025.
Segment Performance
Growth was broad-based across Henry Schein’s reporting segments, with the Global Distribution and Value-Added Services group leading the charge. U.S. dental merchandise sales grew 8.3%, fueled by a combination of pricing actions and volume increases, while international dental merchandise sales surged 11.1%, driven by strong performances in Canada, France, Brazil, and Australia. The Global Specialty Products Group saw an 8.7% sales increase, supported by robust demand for premium implants in Europe and value implants in the U.S., particularly the SIN360 brand. The Global Technology Group also delivered strong results, with total sales rising 8.2%, bolstered by adoption of its Dentrix Ascend cloud-based practice management software.
| Segment | Sales Growth (%) | Key Drivers |
|---|---|---|
| U.S. Dental Merchandise | 8.3% | Pricing, volume gains, market share |
| International Dental Merchandise | 11.1% | Growth in Canada, France, Brazil, Australia |
| Global Specialty Products | 8.7% | Premium implants in Europe, SIN360 in U.S. |
| Global Technology Group | 8.2% | Dentrix Ascend adoption, cloud solutions |
| U.S. Medical Distribution | 3.8% | Government-related, home solutions growth |
What the Numbers Show
A notable divergence exists between revenue growth and earnings acceleration, highlighting the effectiveness of Henry Schein’s margin expansion strategies. While global sales rose 6.7%, non-GAAP EPS jumped 15.5%, indicating that profitability improvements are outpacing top-line growth. This is largely attributable to the shift toward higher-margin businesses, which now account for nearly 50% of total operating income. Additionally, the company’s own-brand products are growing at almost twice the rate of other merchandise sales, further enhancing gross margins. The expansion in non-GAAP operating margin by 25 basis points to 7.21% confirms that operational rigor and portfolio optimization are yielding tangible financial benefits beyond simple volume increases.
Strategic Initiatives and Guidance
Management emphasized its commitment to delivering at least $200 million in operating income improvements from value creation initiatives over the next few years, with a target run rate of $125 million by the end of 2026. Approximately 40% of these savings are expected to come from gross profit initiatives, including dynamic pricing and supply chain efficiencies, while 60% will stem from general and administrative expense reductions. The company repurchased approximately 2.6 million shares for $200 million during the quarter, leaving $455 million authorized for future buybacks. Full-year 2026 non-GAAP diluted EPS guidance was raised to a range of $5.29 to $5.39, up from the previous estimate of $5.23 to $5.37, assuming no further remeasurement gains and consistent foreign exchange rates.
How might the increasing adoption of AI-enabled technology platforms impact Henry Schein's competitive moat against traditional distributors and direct-to-consumer healthcare providers?
Given the strong performance of private-label brands like SIN360, what are the potential risks regarding supplier relationships or regulatory scrutiny as the company shifts its portfolio toward higher-margin own-brand products?
With $455 million remaining in authorized share buybacks, how likely is Henry Schein to accelerate capital return programs if the current margin expansion trajectory continues beyond the 2026 guidance period?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
